Vandetanib and Sirolimus in Patients With Recurrent Glioblastoma

NCT00821080 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

33

Enrollment

OTHER

Sponsor class

Conditions

Glioblastoma

Interventions

DRUG: Sirolimus
DRUG: Vandetanib

Sponsor

Massachusetts General Hospital

Collaborators

[object Object]
[object Object]
[object Object]